

Arun K. Ghosh and Sandra Gemma

Structure-based Design of Drugs and Other Bioactive Molecules

Tools and Strategies

Contents

Preface *XIII*

1 From Traditional Medicine to Modern Drugs: Historical Perspective of Structure-Based Drug Design 1

- 1.1 Introduction 1
- 1.2 Drug Discovery During 1928–1980 1
- 1.3 The Beginning of Structure-Based Drug Design 6
- 1.4 Conclusions 12
- References 13

Part One Concepts, Tools, Ligands, and Scaffolds for Structure-Based Design of Inhibitors 19

2 Design of Inhibitors of Aspartic Acid Proteases 21

- 2.1 Introduction 21
- 2.2 Design of Peptidomimetic Inhibitors of Aspartic Acid Proteases 22
- 2.3 Design of Statine-Based Inhibitors 24
- 2.4 Design of Hydroxyethylene Isostere-Based Inhibitors 29
- 2.5 Design of Inhibitors with Hydroxyethylamine Isosteres 35
- 2.5.1 Synthesis of Optically Active α -Aminoalkyl Epoxide 37
- 2.6 Design of (Hydroxyethyl)urea-Based Inhibitors 40
- 2.7 (Hydroxyethyl)sulfonamide-Based Inhibitors 42
- 2.8 Design of Heterocyclic/Nonpeptidomimetic Aspartic Acid Protease Inhibitors 42
- 2.8.1 Hydroxycoumarin- and Hydroxypyrrone-Based Inhibitors 44
- 2.8.2 Design of Substituted Piperidine-Based Inhibitors 46
- 2.8.3 Design of Diaminopyrimidine-Based Inhibitors 50
- 2.8.4 Design of Acyl Guanidine-Based Inhibitors 51
- 2.8.5 Design of Aminopyridine-Based Inhibitors 53
- 2.8.6 Design of Aminoimidazole- and Aminohydantoin-Based Inhibitors 53
- 2.9 Conclusions 56
- References 56

3	Design of Serine Protease Inhibitors	67
3.1	Introduction	67
3.2	Catalytic Mechanism of Serine Protease	67
3.3	Types of Serine Protease Inhibitors	67
3.4	Halomethyl Ketone-Based Inhibitors	69
3.5	Diphenyl Phosphonate-Based Inhibitors	70
3.6	Trifluoromethyl Ketone Based Inhibitors	73
3.6.1	Synthesis of Trifluoromethyl Ketones	76
3.7	Peptidyl Boronic Acid-Based Inhibitors	78
3.7.1	Synthesis of α -Aminoalkyl Boronic Acid Derivatives	83
3.8	Peptidyl α -Ketoamide- and α -Ketoheterocycle-Based Inhibitors	85
3.8.1	Synthesis of α -Ketoamide and α -Ketoheterocyclic Templates	90
3.9	Design of Serine Protease Inhibitors Based Upon Heterocycles	93
3.9.1	Isocoumarin-Derived Irreversible Inhibitors	94
3.9.2	β -Lactam-Derived Irreversible Inhibitors	95
3.10	Reversible/Noncovalent Inhibitors	97
3.11	Conclusions	104
	References	105
4	Design of Proteasome Inhibitors	113
4.1	Introduction	113
4.2	Catalytic Mechanism of 20S Proteasome	113
4.3	Proteasome Inhibitors	114
4.3.1	Development of Boronate Proteasome Inhibitors	115
4.3.2	Development of β -Lactone Natural Product-Based Proteasome Inhibitors	116
4.3.3	Development of Epoxy Ketone-Derived Inhibitors	118
4.3.4	Noncovalent Proteasome Inhibitors	120
4.4	Synthesis of β -Lactone Scaffold	121
4.5	Synthesis of Epoxy Ketone Scaffold	123
4.6	Conclusions	126
	References	126
5	Design of Cysteine Protease Inhibitors	131
5.1	Introduction	131
5.2	Development of Cysteine Protease Inhibitors with Michael Acceptors	132
5.3	Design of Noncovalent Cysteine Protease Inhibitors	136
5.4	Conclusions	140
	References	140
6	Design of Metalloprotease Inhibitors	143
6.1	Introduction	143
6.2	Design of Matrix Metalloprotease Inhibitors	144

6.3	Design of Inhibitors of Tumor Necrosis Factor- α -Converting Enzymes	150
6.4	Conclusions	152
	References	152
7	Structure-Based Design of Protein Kinase Inhibitors	155
7.1	Introduction	155
7.2	Active Site of Protein Kinases	155
7.3	Catalytic Mechanism of Protein Kinases	156
7.4	Design Strategy for Protein Kinase Inhibitors	156
7.5	Nature of Kinase Inhibitors Based upon Binding	160
7.5.1	Type I Kinase Inhibitors and Their Design	160
7.5.2	Type II Kinase Inhibitors and Their Design	164
7.5.3	Allosteric Kinase Inhibitors and Their Design	168
7.5.4	Covalent Kinase Inhibitors and Their Design	172
7.6	Conclusions	177
	References	177
8	Protein X-Ray Crystallography in Structure-Based Drug Design	183
8.1	Introduction	183
8.2	Protein Expression and Purification	184
8.3	Synchrotron Radiation	185
8.4	Structural Biology in Fragment-Based Drug Design	186
8.5	Selected Examples of Fragment-Based Studies	187
8.6	Conclusions	196
	References	197
9	Structure-Based Design Strategies for Targeting G-Protein-Coupled Receptors (GPCRs)	199
9.1	Introduction	199
9.2	High-Resolution Structures of GPCRs	200
9.3	Virtual Screening Applied to the β_2 -Adrenergic Receptor	201
9.4	Structure-Based Design of Adenosine A_{2A} Receptor Antagonists	204
9.5	Structure-Guided Design of CCR5 Antagonists	207
9.5.1	Development of Maraviroc from HTS Lead Molecules	207
9.5.2	Improvement of Antiviral Activity and Reduction of Cytochrome P450 Activity	208
9.5.3	Reduction of hERG Activity and Optimization of Pharmacokinetic Profile	209
9.5.4	Other CCR5 Antagonists	213
9.6	Conclusion	213
	References	213

Part Two Structure-Based Design of FDA-Approved Inhibitor Drugs and Drugs Undergoing Clinical Development 217

10	Angiotensin-Converting Enzyme Inhibitors for the Treatment of Hypertension: Design and Discovery of Captopril	219
10.1	Introduction	219
10.2	Design of Captopril: the First Clinically Approved Angiotensin-Converting Enzyme Inhibitor	220
10.3	Structure of Angiotensin-Converting Enzyme	225
10.4	Design of ACE Inhibitors Containing a Carboxylate as Zinc Binding Group	228
10.5	ACE Inhibitors Bearing Phosphorus-Based Zinc Binding Groups	231
10.5.1	Phosphoramidate-Based Inhibitors	232
10.5.2	Phosphonic and Phosphinic Acid Derivatives: the Path to Fosinopril	233
10.6	Conclusions	234
	References	235
11	HIV-1 Protease Inhibitors for the Treatment of HIV Infection and AIDS: Design of Saquinavir, Indinavir, and Darunavir	237
11.1	Introduction	237
11.2	Structure of HIV Protease and Design of Peptidomimetic Inhibitors Containing Transition-State Isosteres	239
11.3	Saquinavir: the First Clinically Approved HIV-1 Protease Inhibitor	241
11.4	Indinavir: an HIV Protease Inhibitor Containing the Hydroxyethylene Transition-State Isostere	246
11.5	Design and Development of Darunavir	251
11.6	Design of Cyclic Ether Templates in Drug Discovery	252
11.7	Investigation of Cyclic Sulfones as P_2 Ligands	255
11.8	Design of Bis-tetrahydrofuran and Other Bicyclic P_2 Ligands	257
11.9	The “Backbone Binding Concept” to Combat Drug Resistance: Inhibitor Design Strategy Promoting Extensive Backbone Hydrogen Bonding from S_2 to S_2' Subsites	259
11.10	Design of Darunavir and Other Inhibitors with Clinical Potential	263
11.11	Conclusions	266
	References	266
12	Protein Kinase Inhibitor Drugs for Targeted Cancer Therapy: Design and Discovery of Imatinib, Nilotinib, Bafetinib, and Dasatinib	271
12.1	Introduction	271
12.2	Evolution of Kinase Inhibitors as Anticancer Agents	272
12.3	The Discovery of Imatinib	274
12.4	Imatinib: the Structural Basis of Selectivity	275
12.5	Pharmacological Profile and Clinical Development	278

12.6	Imatinib Resistance	279
12.7	Different Strategies for Combating Drug Resistance	279
12.7.1	Nilotinib and Bafetinib: Optimizing Drug–Target Interactions	279
12.7.2	Dasatinib: Binding to the Active Conformation (the First Example of Dual Abl/Src Inhibitors)	284
12.8	Conclusions	289
	References	290
13	NS3/4A Serine Protease Inhibitors for the Treatment of HCV: Design and Discovery of Boceprevir and Telaprevir	295
13.1	Introduction	295
13.2	NS3/4A Structure	296
13.3	Mechanism of Peptide Hydrolysis by NS3/4A Serine Protease	299
13.4	Development of Mechanism-Based Inhibitors	300
13.5	Strategies for the Development of HCV NS3/4A Protease Inhibitors	303
13.6	Initial Studies toward the Development of Boceprevir	304
13.7	Reduction of Peptidic Character	308
13.8	Optimization of P ₂ Interactions	309
13.9	Truncation Strategy: the Path to Discovery of Boceprevir	312
13.10	The Discovery of Telaprevir	314
13.11	Simultaneous P ₁ , P ₁ ', P ₂ , P ₃ , and P ₄ Optimization Strategy: the Path to Discovery of Telaprevir	316
13.12	Conclusions	319
	References	319
14	Proteasome Inhibitors for the Treatment of Relapsed Multiple Myeloma: Design and Discovery of Bortezomib and Carfilzomib	325
14.1	Introduction	325
14.2	Discovery of Bortezomib	326
14.3	Discovery of Carfilzomib	330
14.4	Conclusions	334
	References	334
15	Development of Direct Thrombin Inhibitor, Dabigatran Etxilate, as an Anticoagulant Drug	337
15.1	Introduction	337
15.2	Coagulation Cascade and Anticoagulant Drugs	338
15.3	Anticoagulant Therapies	340
15.4	Structure of Thrombin	342
15.5	The Discovery of Dabigatran Etxilate	345
15.6	Conclusions	353
	References	353

16	Non-Nucleoside HIV Reverse Transcriptase Inhibitors for the Treatment of HIV/AIDS: Design and Development of Etravirine and Rilpivirine	355
16.1	Introduction	355
16.2	Structure of the HIV Reverse Transcriptase	357
16.3	Discovery of Etravirine and Rilpivirine	360
16.4	Conclusions	368
	References	370
17	Renin Inhibitor for the Treatment of Hypertension: Design and Discovery of Aliskiren	373
17.1	Introduction	373
17.2	Structure of Renin	373
17.3	Peptidic Inhibitors with Transition-State Isosteres	374
17.4	Peptidomimetic Inhibitors	376
17.5	Design of Peptidomimetic Inhibitors	380
17.6	Biological Properties of Aliskiren	393
17.7	Conclusions	393
	References	394
18	Neuraminidase Inhibitors for the Treatment of Influenza: Design and Discovery of Zanamivir and Oseltamivir	397
18.1	Introduction	397
18.2	Discovery of Zanamivir	401
18.3	Discovery of Oseltamivir	403
18.4	Conclusions	407
	References	408
19	Carbonic Anhydrase Inhibitors for the Treatment of Glaucoma: Design and Discovery of Dorzolamide	411
19.1	Introduction	411
19.2	Design and Discovery of Dorzolamide	412
19.3	Conclusions	418
	References	418
20	β-Secretase Inhibitors for the Treatment of Alzheimer's Disease: Preclinical and Clinical Inhibitors	421
20.1	Introduction	421
20.2	β -Secretase and Its X-Ray Structure	422
20.3	Development of First Peptidomimetic BACE Inhibitors	423
20.4	X-Ray Structure of Inhibitor-Bound BACE1	425
20.5	Design and Development of Selective Inhibitors	427
20.6	Design of Small-Molecule Inhibitors with Clinical Potential	431
20.7	GRL-8234 (18) Rescued Cognitive Decline in AD Mice	435
20.8	BACE1 Inhibitors for Clinical Development	436

20.8.1	Development of Clinical Inhibitor, AZD3839	436
20.8.2	Development of Iminopyrimidinone-Based BACE1 Inhibitors	440
20.9	Conclusions	443
	References	444
	Index	449